Stockscreener 앱 받기
3.30
0.30%
0.010
Fortress Biotech Inc 주식(FBIO)의 최신 뉴스
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Q1 2026 Earnings: EPS Misses Estimates Significantly, Stock DeclinesEarnings Weakness Phase - dars.gov.et
Fortress Biotech highlights its biotech portfolio strategy as a Nasdaq-listed micro-cap - ad-hoc-news.de
Mustang Bio (MBIO) Registration Filing Summary - Quartr
Fortress Biotech focuses on specialty pharma growth and licensing model - ad-hoc-news.de
Crinetics Pharmaceuticals Acquired by Fortress Biotech for $10 B - GuruFocus
Technical Reactions to FBIOP Trends in Macro Strategies - Stock Traders Daily
Fortress Biotech (FBIO) Slides 2.14% as Selling Pressure Persists Near Support LevelHigh Dividend Factor - dars.gov.et
Fortress Biotech Inc highlights its specialty pharma model as investors assess long-term prospects - ad-hoc-news.de
Fortress Biotech, Inc. Actuals & Estimates (NASDAQ:FBIO) - TradingView
Trading the Move, Not the Narrative: (FBIOP) Edition - Stock Traders Daily
Fortress Biotech, Inc.9.375% Series A Cumulative Redeemable Perpetual Preferred Stock - TradingView
FBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes - Yahoo Finance
Fortress Biotech (NASDAQ: FBIO) CFO receives 400,000 RSU award - Stock Titan
Form 4 Fortress Biotech Inc For: 24 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Fortress Biotech, Inc. – NASDAQ:FBIO - TradingView
Fortress Biotech (NASDAQ: FBIO) reports 2026 director and auditor vote tallies - Stock Titan
Fortress Biotech Inc (FBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fortress Biotech StockSaturday deep dive on the business model - AD HOC NEWS
Fortress Biotech Inc (FBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Fortress Biotech Inc (FBIO) Institutional Confidence - TradingKey
Fortress Biotech Inc (FBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fortress Biotech Inc (FBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Fortress Biotech Inc (FBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mustang Bio Inc (MBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech (FBIO) AGM 2026 Summary - Quartr
Fortress Biotech Inc Annual Shareholders Meeting Transcript - GuruFocus
Fortress Biotech Inc (FBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fortress Biotech Inc (FBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fortress Biotech Inc (FBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Fortress Biotech Inc. Q4 2025 Earnings: EPS Misses Estimates, Stock Rises Amid Strategic UpdateRevenue Miss Report - dars.gov.et
(FBIOP) Volatility Zones as Tactical Triggers - Stock Traders Daily
FBIOP Q4 2025 Earnings: Preferred Stock Reports Wider-than-Expected Loss Amid Narrowing Pipeline Progress - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Edges Higher Before Resistance TestPut Support - newsline.com
Why Is Fortress Biotech Stock Falling Today? - MSN
FBIOP Q4 2025 Earnings: Preferred Stock Faces EPS Miss as Company Reports LossEPS Revision Trend - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Faces Resistance, Slides 2.3% in Quiet SessionProtective Put - newsline.com
Fortress Biotech Preferred Stock (FBIOP) Pulls Back 2.3% as Shares Approach Key SupportDescending Triangle - newsline.com
Price-Driven Insight from (FBIOP) for Rule-Based Strategy - Stock Traders Daily
Fortress Biotech Inc stock (US32015L1035): Nasdaq-listed biotech moves in low-volume trade ahead of - AD HOC NEWS
Fortress Biotech Preferred Stock (FBIOP) Surges 5.19%, Nears Key Resistance at $21.5BPI Bear Confirmed - newsline.com
Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? (FBIO) - Seeking Alpha
FBIO Q4 2025 Earnings: EPS Misses Estimates as Revenue Remains AbsentEarnings Seasonality - The Legal Advocate
Fortress Biotech Preferred (FBIOP) Rises 2.37%; Support and Resistance in FocusSynthetic Long - The Legal Advocate
FBIOFortress Biotech Inc Stock Price and Quote - Finviz
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q1 2026 shows 21% revenue rise - Investing.com Canada
FBIOP Q4 2025 Earnings: Preferred Stock Reports Negative EPS Surprise Amid No Revenue Disclosure - newsline.com
Fortress Biotech Preferred Shares (FBIOP) Advance 2.45% as Support Holds Near $16Dark Pool Prints - The Legal Advocate
FBIO Q4 2025 Earnings: Deep EPS Miss Highlights Challenges for Pre-Revenue BiotechTrough Earnings Signal - Newser
(FBIOP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Fortress Biotech Preferred Stock (FBIOP) Q4 2025 Earnings: EPS Misses Estimates by Over 108%Community Sell Signals - Newser
Fortress Biotech (FBIO) Gains 1.62% as Shares Approach Key Resistance at $2.97Stock Analysis - Newser
Fortress Biotech Inc. (FBIO) Moves Higher as Buyers Defend Key Support LevelLarge Cap Trends - The Legal Advocate
2.64%
자본화:
|
볼륨(24시간):